Unraveling chemotherapy-evoked hepatic dysfunction: a deep dive into cyclophosphamide-related liver injury
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-01 · 399 (2) · 2097-2112
DOI: 10.1007/s00210-025-04583-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 27.09.2025. Verfasst von Ehab E Sharata und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, Faculty of Pharmacy, Deraya University, Minia, 61111, Egypt. ehab.essam@deraya.edu.eg. Hauptthemen laut MEDLINE: Cyclophosphamide, Chemical and Drug Induced Liver Injury, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deraya University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cyclophosphamide (CPA) is an alkylating drug utilized in the treatment of several cancers and autoimmune illnesses. Liver injury is a serious adverse effect linked to the administration of CPA. Nonetheless, the mechanism behind this toxicity remains incompletely elucidated; mechanistic investigations have identified oxidative stress, inflammatory responses, and apoptosis as pivotal elements contributing to CPA-induced liver dysfunction. In addition, CPA triggers the production of reactive oxygen species that act as damage-associated molecular patterns that rapidly activate TLR4/MYD88/NF-κB and NLRP3 inflammasome signaling cascades. Additionally, Nrf2/HO-1, α-klotho, and P-AMPK, which have anti-inflammatory and antioxidative characteristics, are thought to be important signaling pathways that mitigate oxidative stress in CPA-induced liver dysfunction. This review comprehensively covers all aspects of liver injury, including its epidemiology of drug-induced liver injury, risk factors, clinical presentation, chemotherapy-induced liver injury severity index, pathogenesis of CPA-induced liver injury and molecular mechanisms, and therapeutic choices. This study seeks to consolidate all known data about CPA-evoked liver injury, focusing on the probable redox molecular pathways underlying CPA-induced liver injury and recent drugs that showed a protective impact. In conclusion, studying these molecular pathways might open the way for early alleviation of hepatic dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Deraya University, Minia, 61111, Egypt. ehab.essam@deraya.edu.eg.
- Department of Pathology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62514, Egypt.
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Deraya University, Minia, 61111, Egypt.
- Department of Medical Pharmacology, Faculty of Medicine, Minia University, Minia, 61519, Egypt.
Förderung
- Deraya University
Zitieren
APA
Sharata, E. E., Attya, M. E., Khalaf, M. M., Rofaeil, R. R., Hemeida, R. A. M., & Abo-Youssef, A. M. (2026). Unraveling chemotherapy-evoked hepatic dysfunction: a deep dive into cyclophosphamide-related liver injury. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(2), 2097-2112. https://doi.org/10.1007/s00210-025-04583-0
Vancouver
Sharata EE, Attya ME, Khalaf MM, Rofaeil RR, Hemeida RAM, Abo-Youssef AM. Unraveling chemotherapy-evoked hepatic dysfunction: a deep dive into cyclophosphamide-related liver injury. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(2):2097-2112. doi:10.1007/s00210-025-04583-0
BibTeX
@article{Sharata2026,
author = {Sharata, Ehab E and Attya, Mina Ezzat and Khalaf, Marwa M and Rofaeil, Remon Roshdy and Hemeida, Ramadan A M and Abo-Youssef, Amira M},
title = {Unraveling chemotherapy-evoked hepatic dysfunction: a deep dive into cyclophosphamide-related liver injury},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {2},
pages = {2097--2112},
doi = {10.1007/s00210-025-04583-0}
}
EUVIMED